Related Experiment Video
Updated: Aug 24, 2026

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro
Published on: October 13, 2023
Aberrant glycosylation in IgA nephropathy (IgAN)
Rosanna Coppo1, Alessandro Amore
1Nephrology, Dialysis and Transplantation, Regina Margherita Hospital, Turin, Italy. nefrologia@oirmsantanna.piemonte.it
Abstract:
Immunoglobulin A nephropathy (IgAN) patients exhibit circulating IgA1 with reduced galactose (Gal) and/or sialic acid (Neu5Ac) and increased exposure of N-acetylgalactosamine (GalNAc). These IgA glycoforms fix complement and in mesangial cells regulate integrin expression, enhance nitric oxide synthase (NOS) activity, decrease endothelial growth factor synthesis, meanwhile depressing proliferation and increasing apoptosis. Drugs can be targeted to the effects enhanced by aberrantly glycosylated IgA1 on mesangial cells. Recent data suggest that aberrant IgA1 glycosylation may modulate clinical expression and progression of IgAN.
Related Concept Videos
Proteoglycans
Diabetic Nephropathy
Type I Diabetes I: Introduction
Oligosaccharide Assembly
Multiple sugar molecules that may or may...
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Hyperglycemia

